15, 30 June 2025, article 100188,
We know that for these patients with obesity, diabetes, CKD, cardiovascular disease [CVD], these are really not isolated or distinct entities. However, the research comes at a time when supply chain issues for the GLP-1 receptor agonists have been pronounced and prolonged
in: PubMed | Google Scholar Authorship note: ZC and XD contributed equally to this work
If you have diabetes and are taking insulin or sulfonylureas alongside GLP-1 therapy, be alert for hypoglycaemia symptoms and discuss dose adjustments with your healthcare team
Having compassion and empathy for a person whose experience is different from your own can go a long way to creating a safe space for us all to live, with the bodies and history that we have
Why Its Worth the Wait Each new drug is tested not just for weight loss but also for long-term safety